[Federal Register Volume 60, Number 239 (Wednesday, December 13, 1995)]
[Notices]
[Pages 64078-64079]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 95-30284]



-----------------------------------------------------------------------


DEPARTMENT OF JUSTICE

Notice Pursuant to the National Cooperative Research and 
Production Act of 1993--Arrayed Primer Extension (APEX) Research 
Consortium

    Notice is hereby given that, on September 26, 1995, pursuant to 
Section 6(a) of the National Cooperative Research and Production Act of 
1993, 15 U.S.C. 4301 et seq. (``the Act''), Arrayed Primer Extension 
(APEX) Research Consortium, a joint venture formed as a cooperative 
research consortium by the parties set forth in this notice (the 
``Joint Venture''), has filed written notifications simultaneously with 
the Attorney General and the Federal Trade Commission disclosing (1) 
the identities of the parties to the Joint Venture and (2) the nature 
and objectives of the Joint Venture. The notifications were filed for 
the purpose of invoking the Act's provisions limiting the recovery of 
antitrust plaintiff to actual damages under specified circumstances. 
Pursuant to Section 6(b) of the Act, the identities of the parties are: 
Pharmacia Biotech, Inc., Piscataway, NJ; Baylor College of Medicine, 
Houston, TX; Duke University, Durham, NC; and 

[[Page 64079]]
Indentigene, Inc., Houston, TX. The general area of planned activity is 
to develop and demonstrate arrayed primer extension DNA analysis 
systems for sequencing in DNA diagnosis.
Constance K. Robinson,
Director of Operations, Antitrust Division.
[FR Doc. 95-30284 Filed 12-12-95; 8:45 am]
BILLING CODE 4410-01-M